KW-6002 (Kyowa Hakko Kogyo).

  title={KW-6002 (Kyowa Hakko Kogyo).},
  author={Linda Knutsen and Scott M Weiss},
  journal={Current opinion in investigational drugs},
  volume={2 5},
Kyowa Hakko is developing KW-6002, an adenosine A2A receptor antagonist, for the potential treatment of Parkinson's disease (PD) [183211]. The company subsequently began evaluating the compound for depression, and in June 2000 initiated a phase II trial for this indication. Good results have been obtained in a preclinical depression model and Kyowa Hakko hopes that KW-6002 will be representative of a new class of antidepressants [376107]. KW-6002 is undergoing phase II trials for PD in Japan… CONTINUE READING


Publications citing this paper.
Showing 1-7 of 7 extracted citations

Similar Papers

Loading similar papers…